SUPPLEMENT

Q1 2021 — Sales of Key Products/Franchises

Q1 2021PDF · 7 pages123 KB
REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
2021 	2020 	Reported 	Operational (1) 	Currency
CONSUMER HEALTH SEGMENT (2)
OTC
US 	599	$ 	689 	-13.0% 	-13.0% 	-
Intl 	575 	659 	-12.8% 	-16.6% 	3.8%
WW 	1,175 	1,348 	-12.9% 	-14.8% 	1.9%
SKIN HEALTH / BEAUTY
US 	634 	659 	-3.9% 	-3.9% 	-
Intl 	529 	458 	15.7% 	12.3% 	3.4%
WW 	1,163 	1,117 	4.1% 	2.8% 	1.3%
ORAL CARE
US 	163 	176 	-7.2% 	-7.2% 	-
Intl 	254 	219 	16.0% 	13.9% 	2.1%
WW 	417 	395 	5.7% 	4.5% 	1.2%
BABY CARE
US 	96 	92 	4.2% 	4.2% 	-
Intl 	293 	269 	8.9% 	11.3% 	-2.4%
WW 	389 	361 	7.7% 	9.5% 	-1.8%
WOMEN'S HEALTH
US 	3 	4 	-25.8% 	-25.8% 	-
Intl 	219 	228 	-3.9% 	-2.2% 	-1.7%
WW 	222 	232 	-4.3% 	-2.6% 	-1.7%
WOUND CARE / OTHER
US 	115 	119 	-3.0% 	-3.0% 	-
Intl 	61 	52 	17.6% 	14.2% 	3.4%
WW 	177 	171 	3.3% 	2.2% 	1.1%
TOTAL CONSUMER HEALTH
US 	1,611 	1,740 	-7.4% 	-7.4% 	-
Intl 	1,932 	1,885 	2.5% 	0.5% 	2.0%
WW 	3,543	$ 	3,625 	-2.3% 	-3.3% 	1.0%
See footnotes at end of schedule
% Change

-- 1 of 7 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
PHARMACEUTICAL SEGMENT (2,3) 	2021 	2020 	Reported 	Operational (1) 	Currency
IMMUNOLOGY
US 	2,413	$ 	2,410 	0.1% 	0.1% 	-
Intl 	1,501 	1,228 	22.3% 	15.9% 	6.4%
WW 	3,914 	3,638 	7.6% 	5.5% 	2.1%
REMICADE
US 	489 	625 	-21.7% 	-21.7% 	-
US Exports (4) 	57 	110 	-48.4% 	-48.4% 	-
Intl 	232 	256 	-9.4% 	-12.1% 	2.7%
WW 	777 	990 	-21.5% 	-22.2% 	0.7%
SIMPONI / SIMPONI ARIA
US 	255 	272 	-5.9% 	-5.9% 	-
Intl 	307 	258 	18.9% 	13.8% 	5.1%
WW 	562 	529 	6.2% 	3.7% 	2.5%
STELARA
US 	1,331 	1,217 	9.4% 	9.4% 	-
Intl 	817 	603 	35.6% 	27.6% 	8.0%
WW 	2,148 	1,819 	18.1% 	15.4% 	2.7%
TREMFYA
US 	274 	187 	46.3% 	46.3% 	-
Intl 	143 	109 	32.0% 	23.1% 	8.9%
WW 	418 	296 	41.0% 	37.8% 	3.2%
OTHER IMMUNOLOGY
US 	7 	- 	* 	* 	-
Intl 	2 	3 	-38.4% 	-36.3% 	-2.1%
WW 	8 	3 	* 	* 	*
INFECTIOUS DISEASES
US 	512 	436 	17.4% 	17.4% 	-
Intl 	494 	483 	2.3% 	-2.2% 	4.5%
WW 	1,007 	920 	9.5% 	7.1% 	2.4%
COVID-19 VACCINE
US 	100 	- 	* 	* 	-
Intl 	- 	- 	- 	- 	-
WW 	100 	- 	* 	* 	-
EDURANT / rilpivirine
US 	10 	12 	-12.3% 	-12.3% 	-
Intl 	233 	212 	9.8% 	0.9% 	8.9%
WW 	243 	224 	8.6% 	0.2% 	8.4%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 	380 	396 	-3.8% 	-3.8% 	-
Intl 	166 	184 	-9.9% 	-10.4% 	0.5%
WW 	546 	579 	-5.8% 	-5.9% 	0.1%
OTHER INFECTIOUS DISEASES
US 	21 	29 	-27.0% 	-27.0% 	-
Intl 	96 	87 	9.7% 	7.4% 	2.3%
WW 	117 	116 	0.6% 	-1.2% 	1.8%
% Change

-- 2 of 7 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
2021 	2020 	Reported 	Operational (1) 	Currency
NEUROSCIENCE
US 	771 	748 	3.2% 	3.2% 	-
Intl 	949 	910 	4.3% 	0.4% 	3.9%
WW 	1,721 	1,658 	3.8% 	1.6% 	2.2%
CONCERTA / Methylphenidate
US 	47 	52 	-9.6% 	-9.6% 	-
Intl 	123 	118 	4.5% 	-0.4% 	4.9%
WW 	171 	171 	0.2% 	-3.2% 	3.4%
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 	589 	544 	8.3% 	8.3% 	-
Intl 	376 	339 	11.0% 	4.5% 	6.5%
WW 	965 	883 	9.4% 	6.9% 	2.5%
RISPERDAL CONSTA
US 	67 	76 	-11.8% 	-11.8% 	-
Intl 	89 	94 	-4.8% 	-8.8% 	4.0%
WW 	157 	170 	-7.9% 	-10.1% 	2.2%
OTHER NEUROSCIENCE
US 	67 	75 	-9.8% 	-9.8% 	-
Intl 	361 	360 	0.2% 	-0.9% 	1.1%
WW 	428 	435 	-1.5% 	-2.5% 	1.0%
ONCOLOGY
US 	1,377 	1,175 	17.2% 	17.2% 	-
Intl 	2,193 	1,839 	19.3% 	12.9% 	6.4%
WW 	3,570 	3,013 	18.5% 	14.6% 	3.9%
DARZALEX
US 	691 	463 	49.2% 	49.2% 	-
Intl 	674 	474 	42.2% 	35.3% 	6.9%
WW 	1,365 	937 	45.6% 	42.2% 	3.4%
ERLEADA
US 	171 	119 	44.0% 	44.0% 	-
Intl 	90 	24 	* 	* 	*
WW 	261 	143 	82.8% 	79.7% 	3.1%
IMBRUVICA
US 	444 	432 	2.8% 	2.8% 	-
Intl 	680 	599 	13.5% 	7.6% 	5.9%
WW 	1,125 	1,031 	9.0% 	5.6% 	3.4%
ZYTIGA / abiraterone acetate
US 	50 	139 	-64.2% 	-64.2% 	-
Intl 	588 	552 	6.6% 	0.0% 	6.6%
WW 	638 	690 	-7.6% 	-12.9% 	5.3%
OTHER ONCOLOGY (5)
US 	21 	22 	-5.1% 	-5.1% 	-
Intl 	161 	190 	-15.3% 	-19.3% 	4.0%
WW 	182 	212 	-14.2% 	-17.9% 	3.7%
% Change

-- 3 of 7 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
2021 	2020 	Reported 	Operational (1) 	Currency
PULMONARY HYPERTENSION
US 	573 	486 	18.0% 	18.0% 	-
Intl 	288 	260 	10.8% 	5.6% 	5.2%
WW 	861 	745 	15.5% 	13.7% 	1.8%
OPSUMIT
US 	272 	229 	18.5% 	18.5% 	-
Intl 	179 	160 	11.5% 	6.3% 	5.2%
WW 	450 	389 	15.6% 	13.5% 	2.1%
UPTRAVI
US 	259 	212 	21.9% 	21.9% 	-
Intl 	46 	38 	23.0% 	15.7% 	7.3%
WW 	305 	250 	22.0% 	20.9% 	1.1%
OTHER PULMONARY HYPERTENSION
US 	42 	44 	-3.5% 	-3.5% 	-
Intl 	63 	62 	1.4% 	-2.1% 	3.5%
WW 	105 	106 	-0.6% 	-2.7% 	2.1%
CARDIOVASCULAR / METABOLISM / OTHER
US 	799 	806 	-0.9% 	-0.9% 	-
Intl 	328 	354 	-7.2% 	-11.3% 	4.1%
WW 	1,127 	1,160 	-2.8% 	-4.1% 	1.3%
XARELTO
US 	589 	527 	11.7% 	11.7% 	-
Intl 	- 	- 	- 	- 	-
WW 	589 	527 	11.7% 	11.7% 	-
INVOKANA / INVOKAMET
US 	87 	117 	-26.1% 	-26.1% 	-
Intl 	63 	58 	9.2% 	4.2% 	5.0%
WW 	150 	175 	-14.4% 	-16.1% 	1.7%
PROCRIT / EPREX
US 	62 	76 	-18.3% 	-18.3% 	-
Intl 	64 	79 	-18.1% 	-22.2% 	4.1%
WW 	127 	155 	-18.2% 	-20.3% 	2.1%
OTHER
US 	60 	85 	-28.8% 	-28.8% 	-
Intl 	201 	217 	-7.7% 	-11.5% 	3.8%
WW 	261 	302 	-13.6% 	-16.4% 	2.8%
TOTAL PHARMACEUTICAL
US 	6,446 	6,061 	6.4% 	6.4% 	-
Intl 	5,753 	5,073 	13.4% 	7.9% 	5.5%
WW 	12,199	$ 	11,134 	9.6% 	7.1% 	2.5%
See footnotes at end of schedule
% Change

-- 4 of 7 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
MEDICAL DEVICES SEGMENT (2) 	2021 	2020 	Reported 	Operational (1) 	Currency
INTERVENTIONAL SOLUTIONS
US 	434	$ 	365 	19.0% 	19.0% 	-
Intl 	514 	362 	42.0% 	34.0% 	8.0%
WW 	949 	727 	30.4% 	26.4% 	4.0%
ORTHOPAEDICS
US 	1,249 	1,250 	-0.1% 	-0.1% 	-
Intl 	864 	788 	9.7% 	3.1% 	6.6%
WW 	2,113 	2,038 	3.7% 	1.2% 	2.5%
HIPS
US 	210 	206 	2.4% 	2.4% 	-
Intl 	146 	132 	11.2% 	4.5% 	6.7%
WW 	357 	337 	5.8% 	3.2% 	2.6%
KNEES
US 	185 	214 	-13.5% 	-13.5% 	-
Intl 	132 	130 	2.0% 	-4.1% 	6.1%
WW 	317 	343 	-7.6% 	-9.9% 	2.3%
TRAUMA
US 	450 	407 	10.7% 	10.7% 	-
Intl 	282 	247 	14.4% 	7.7% 	6.7%
WW 	733 	654 	12.1% 	9.5% 	2.6%
SPINE, SPORTS & OTHER
US 	403 	423 	-4.8% 	-4.8% 	-
Intl 	303 	280 	8.4% 	1.7% 	6.7%
WW 	706 	703 	0.4% 	-2.2% 	2.6%
% Change

-- 5 of 7 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
2021 	2020 	Reported 	Operational (1) 	Currency
SURGERY
US 	898 	844 	6.5% 	6.5% 	-
Intl 	1,474 	1,257 	17.3% 	11.7% 	5.6%
WW 	2,372 	2,100 	12.9% 	9.6% 	3.3%
ADVANCED
US 	405 	381 	6.5% 	6.5% 	-
Intl 	713 	567 	25.7% 	19.5% 	6.2%
WW 	1,118 	948 	18.0% 	14.3% 	3.7%
GENERAL
US 	493 	463 	6.5% 	6.5% 	-
Intl 	761 	690 	10.3% 	5.3% 	5.0%
WW 	1,254 	1,153 	8.8% 	5.8% 	3.0%
VISION
US 	472 	439 	7.4% 	7.4% 	-
Intl 	673 	628 	7.3% 	3.9% 	3.4%
WW 	1,145 	1,067 	7.3% 	5.4% 	1.9%
CONTACT LENSES / OTHER
US 	371 	346 	7.2% 	7.2% 	-
Intl 	486 	467 	4.0% 	0.9% 	3.1%
WW 	857 	814 	5.3% 	3.5% 	1.8%
SURGICAL
US 	101 	93 	8.2% 	8.2% 	-
Intl 	187 	160 	17.0% 	12.9% 	4.1%
WW 	288 	253 	13.7% 	11.2% 	2.5%
TOTAL MEDICAL DEVICES
US 	3,054 	2,898 	5.4% 	5.4% 	-
Intl 	3,525 	3,034 	16.2% 	10.5% 	5.7%
WW 	6,579	$ 	5,932 	10.9% 	8.0% 	2.9%
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Certain prior year amounts have been reclassified to conform to current year product disclosures
(4) Reported as U.S. sales
(5) Refer to supplemental schedule
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely.
% Change

-- 6 of 7 --

Full Year 	Q1 	Q2 	Q3 	Q4 	Full Year
PHARMACEUTICAL SEGMENT(1)
Oncology
OTHER ONCOLOGY(2)
US 	70 	22 	20 	21 	20 	83
Intl 	1,087 	190 	185 	181 	183 	738
WW 	1,158 	212 	204 	203 	202 	821
Note: Columns and rows within tables may not add due to rounding.
(1) Unaudited
(2) Other Oncology is inclusive of VELCADE, which was previously disclosed separately
Supplemental Sales Information
(Dollars in Millions)
Prior quarter amounts have been reclassified to
conform to current quarter product disclosure
2019 	2020 	2020

-- 7 of 7 --